JP2009515901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515901A5 JP2009515901A5 JP2008540275A JP2008540275A JP2009515901A5 JP 2009515901 A5 JP2009515901 A5 JP 2009515901A5 JP 2008540275 A JP2008540275 A JP 2008540275A JP 2008540275 A JP2008540275 A JP 2008540275A JP 2009515901 A5 JP2009515901 A5 JP 2009515901A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- treatment
- inhibitor
- patient
- inhibitor according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73676305P | 2005-11-14 | 2005-11-14 | |
| US60/736,763 | 2005-11-14 | ||
| PCT/US2006/044146 WO2007059106A2 (en) | 2005-11-14 | 2006-11-14 | Administration of mntor inhibitor to treat patients with cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013191029A Division JP2014012721A (ja) | 2005-11-14 | 2013-09-13 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515901A JP2009515901A (ja) | 2009-04-16 |
| JP2009515901A5 true JP2009515901A5 (enExample) | 2010-01-21 |
| JP5709354B2 JP5709354B2 (ja) | 2015-04-30 |
Family
ID=38049229
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008540275A Expired - Fee Related JP5709354B2 (ja) | 2005-11-14 | 2006-11-14 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
| JP2013191029A Pending JP2014012721A (ja) | 2005-11-14 | 2013-09-13 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013191029A Pending JP2014012721A (ja) | 2005-11-14 | 2013-09-13 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070185150A1 (enExample) |
| EP (2) | EP1962839A4 (enExample) |
| JP (2) | JP5709354B2 (enExample) |
| CN (2) | CN101360495B (enExample) |
| AU (1) | AU2006315512B2 (enExample) |
| CA (1) | CA2629714A1 (enExample) |
| EA (1) | EA015922B1 (enExample) |
| IL (1) | IL191356A0 (enExample) |
| WO (1) | WO2007059106A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2054061A4 (en) * | 2006-08-02 | 2009-09-02 | Ariad Pharma Inc | COMBINATION THERAPY |
| AU2007319825B2 (en) * | 2006-11-14 | 2014-01-23 | Ariad Pharmaceuticals, Inc. | Oral formulations |
| AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| ES2645692T3 (es) | 2008-11-11 | 2017-12-07 | The Board Of Regents,The University Of Texas System | Microcápsulas de rapamicina y su uso para el tratamiento del cáncer |
| CN102481361B (zh) | 2009-04-16 | 2014-10-22 | 默沙东公司 | 用于治疗癌症的组合物和方法 |
| US8911766B2 (en) * | 2009-06-26 | 2014-12-16 | Abbott Cardiovascular Systems Inc. | Drug delivery compositions including nanoshells for triggered drug release |
| WO2011024168A2 (en) * | 2009-08-26 | 2011-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd | Sustained release delivery systems for the prevention and treatment of head and neck cancers |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| AU2011240735B2 (en) * | 2010-04-13 | 2015-01-29 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer |
| JP2012061053A (ja) | 2010-09-14 | 2012-03-29 | Yuuki Kitaoka | 投薬装置、投薬装置の作動方法及び投薬方法 |
| AR083267A1 (es) * | 2010-10-04 | 2013-02-13 | Novartis Ag | Combinaciones farmaceuticas |
| JP6086902B2 (ja) * | 2011-04-25 | 2017-03-01 | ノバルティス アーゲー | ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤およびｍＴＯＲ阻害剤の組み合わせ |
| BR112014013332B1 (pt) * | 2011-12-02 | 2022-09-06 | Signal Pharmaceuticals, Llc | Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso |
| BR112014028420A2 (pt) * | 2012-05-16 | 2017-09-19 | Novartis Ag | regime de dosagem para um inibidor de quinase pi-3 |
| WO2014078522A1 (en) * | 2012-11-14 | 2014-05-22 | Ohio State Innovation Foundation | Materials and methods useful for treating glioblastoma |
| EP2968281B1 (en) | 2013-03-13 | 2020-08-05 | The Board of Regents of The University of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| CN104721158B (zh) * | 2013-12-24 | 2018-01-30 | 正大天晴药业集团股份有限公司 | 一种稳定的依维莫司片剂 |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| DK3089737T3 (da) | 2013-12-31 | 2021-12-13 | Rapamycin Holdings Llc | Orale rapamycin-nanopartikelpræparater og anvendelse. |
| CN106166296A (zh) * | 2016-07-01 | 2016-11-30 | 江南大学 | 一种辅助雷帕霉素治疗多种肿瘤的药物组合物 |
| CN107714719A (zh) * | 2017-11-08 | 2018-02-23 | 上海市第妇婴保健院 | 雷帕霉素在制备治疗白细胞介素‑27低表达子宫内膜癌的药物中的应用 |
| JP7530116B2 (ja) * | 2020-02-21 | 2024-08-07 | コリア アドヴァンスド インスティテュート オブ サイエンス アンド テクノロジー | エムトール信号伝達抑制剤を有効成分として含む癌の予防又は治療用薬剤学的組成物 |
| CN114767867A (zh) * | 2021-12-22 | 2022-07-22 | 中山大学孙逸仙纪念医院 | 一种用于治疗cdk4/6抑制剂耐药后的乳腺癌的药物组合物及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
| US5078999A (en) | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
| US5080899A (en) | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
| US5321009A (en) | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
| DE69209183T2 (de) | 1991-06-18 | 1996-08-08 | American Home Prod | Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen |
| ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
| US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| US5288711A (en) | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
| ES2176245T3 (es) | 1993-04-23 | 2002-12-01 | Wyeth Corp | Anticuerpos de ramapicinas de ciclo abierto. |
| CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| EP0649651B1 (en) | 1993-09-28 | 2000-12-13 | R.P. Scherer GmbH | Soft gelatin capsule manufacture |
| US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
| US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| GB0000482D0 (en) | 2000-01-11 | 2000-03-01 | Norton Healthcare Ltd | Enteric coated pharmaceutical formulation |
| EP3342411B1 (en) | 2001-02-19 | 2019-08-21 | Novartis Pharma AG | Rapamycin derivative for treating pancreas cancer |
| PL363991A1 (en) * | 2001-04-06 | 2004-11-29 | Wyeth | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
| CN100415770C (zh) | 2001-05-30 | 2008-09-03 | 诺瓦提斯公司 | 2－{[n－(2－氨基－3－(杂芳基或芳基)丙酰基)－氨基酰基]－氨基}－烷基硼酸衍生物 |
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| BR0314397A (pt) | 2002-09-17 | 2005-08-09 | Wyeth Corp | Formulações orais |
| CA2536140A1 (en) * | 2003-08-18 | 2005-02-24 | Pfizer Products Inc. | Dosing schedule for erbb2 anticancer agents |
| GB0327840D0 (en) * | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| PL1701698T3 (pl) | 2004-01-08 | 2008-03-31 | Wyeth Corp | Prasowana bezpośrednio kompozycja farmaceutyczna do podawania doustnego CCI-779 |
| US7405497B2 (en) | 2004-04-13 | 2008-07-29 | Electrovaya Inc. | Integrated power supply system |
| CA2581372A1 (en) * | 2004-09-30 | 2006-04-13 | Ariad Gene Therapeutics, Inc. | Treatment method |
| KR20070104908A (ko) * | 2005-02-15 | 2007-10-29 | 와이어쓰 | 경구적으로 생체이용가능한 ｃｃｉ-779 정제 제형물 |
| GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| DE102005017313A1 (de) | 2005-04-14 | 2006-10-19 | Volkswagen Ag | Verfahren zur Darstellung von Informationen in einem Verkehrsmittel und Kombiinstrument für ein Kraftfahrzeug |
| AR058505A1 (es) * | 2005-11-04 | 2008-02-06 | Wyeth Corp | Combinaciones antineoplasicas de temsirolimus y malato de sunitinib |
-
2006
- 2006-11-14 AU AU2006315512A patent/AU2006315512B2/en not_active Ceased
- 2006-11-14 CN CN2006800510347A patent/CN101360495B/zh not_active Expired - Fee Related
- 2006-11-14 JP JP2008540275A patent/JP5709354B2/ja not_active Expired - Fee Related
- 2006-11-14 EA EA200801309A patent/EA015922B1/ru not_active IP Right Cessation
- 2006-11-14 EP EP06844354A patent/EP1962839A4/en not_active Withdrawn
- 2006-11-14 WO PCT/US2006/044146 patent/WO2007059106A2/en not_active Ceased
- 2006-11-14 US US11/598,850 patent/US20070185150A1/en not_active Abandoned
- 2006-11-14 CA CA002629714A patent/CA2629714A1/en not_active Abandoned
- 2006-11-14 CN CN2012100014166A patent/CN102579467A/zh active Pending
- 2006-11-14 EP EP13179744.1A patent/EP2662082A1/en not_active Withdrawn
-
2008
- 2008-05-12 IL IL191356A patent/IL191356A0/en unknown
-
2013
- 2013-09-13 JP JP2013191029A patent/JP2014012721A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515901A5 (enExample) | ||
| JP2009539769A5 (enExample) | ||
| IL273765A (en) | Combinations and forms of administration of therapeutic agents and combined treatment | |
| JP2014040437A5 (enExample) | ||
| JP2008530248A5 (enExample) | ||
| JP2009545601A5 (enExample) | ||
| JP2014512356A5 (enExample) | ||
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| JP2009506054A5 (enExample) | ||
| JP2013518124A5 (enExample) | ||
| JP2015527374A5 (enExample) | ||
| JP2009536956A5 (enExample) | ||
| JP2005530735A5 (enExample) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| JP2008517991A5 (enExample) | ||
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| JP2011500589A5 (enExample) | ||
| JP2015510945A5 (enExample) | ||
| JP2011500650A5 (enExample) | ||
| JP2007538066A5 (enExample) | ||
| JP2010519274A5 (enExample) | ||
| Kalavrezos et al. | Mouth cancer for clinicians part 12: cancer treatment (chemotherapy and targeted therapy) | |
| CY1112814T1 (el) | Αντιμετωπιση ανθεκτικων στα φαρμακα ογκων | |
| HK1133829A (en) | Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer | |
| Lin et al. | Tolerabil ity of Oxal ipltin2based Adjuvant Chemotherapy in Colorectal Cancer Patients |